Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09

International Journal of Epidemiology

Volumn 39, Issue SUPPL. 2, 2010, Pages

  Dou, Zhihui ^a   Chen, Ray Y ^b   Xu, Jiahong ^c   Ma, Ye ^a   Jiao, Jin Hua ^c   Durako, Stephen ^c   Zhao, Yan ^a   Zhao, Decai ^a   Fang, Hua ^a   Zhang, Fujie ^a,d  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c WESTAT   (United States)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Baseline characteristics; China; HIV; Injection drug users; National treatment program; Routine testing

Indexed keywords

BASELINE CONDITIONS; COHORT ANALYSIS; DATABASE; DRUG USER; HEALTH MONITORING; HEALTH POLICY; HEALTH RISK; HEALTH SERVICES; HUMAN IMMUNODEFICIENCY VIRUS; SPATIOTEMPORAL ANALYSIS;

ADULT; ARTICLE; BLOOD DONOR; CD4 LYMPHOCYTE COUNT; CHINA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; CHINA; EPIDEMICS; FEMALE; HIV INFECTIONS; HUMANS; MALE; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS;

CHINA;

EID: 78649792132     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyq215     Document Type: Article

References (36)

1. Zhang FJ, Chen RY, Lo SN, Ma Y. Country review: China. In: Zuniga JM, Whiteside A, Ghaziani A, Bartlett JG (eds). A Decade of HAART. Oxford: Oxford University Press, 2008.
2. Qian HZ, Vermund SH, Wang N. Risk of HIV/AIDS in China: subpopulations of special importance. Sex Transm Infect 2005;81:442-7.
3. He N, Detels R. The HIV epidemic in China: history, response, and challenge. Cell Res 2005;15:825-32.
4. Zhang F, Haberer JE, Wang Y, et al. The Chinese free antiretroviral treatment program: challenges and responses. AIDS 2007;21(Suppl. 8):S143-48.
5. Zhang F, Hsu M, Yu L, Wen Y, Pan J. Initiation of the national free antiretroviral therapy program in rural China. In: Kaufman J, Kleinman A, Saich T (eds). AIDS and Social Policy in China. Cambridge, MA: Harvard University Asia Center, 2006, pp. 96-104.
6. Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y. Current progress of China's free ART program. Cell Res 2005;15: 877-82.
7. Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008;47: 825-33.
8. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009;151:241-51, W-52.
9. Zhang F (ed.) China Free ART Manual. Beijing: Chinese Center for Disease Control and Prevention, 2005.
10. Ma Y, Zhang F, Zhao Y, et al. Cohort profile: the Chinese national free antiretroviral treatment cohort. Int J Epidemiol 2010;39:973-79.
11. Bulterys M, Vermund SH, Chen RY, Ou CY. A public health approach to rapid scale-up of free antiretroviral treatment in China: an ounce of prevention is worth a pound of cure. Chin Med J (Engl) 2009;122:1352-55.
12. Ma Y, Zhao D, Yu L, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 2010;50: 264-71.
13. A Joint Assessment of HIV/AIDS Prevention, Treatment and Care in China (2007). Beijing: State Council AIDS Working Committee Office, UN Theme Group on AIDS in China, 2007.
14. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77.
15. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003;138:620-26.
16. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006;296:782-93.
17. Collaboration ATC. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Syndr 2007; 46:607-15.
18. Wu Z, Sun X, Sullivan SG, Detels R. Public health. HIV testing in China. Science 2006;312:1475-76.
19. Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R. Evolution of China's response to HIV/AIDS. Lancet 2007;369:679-90.
20. Chandisarewa W, Stranix-Chibanda L, Chirapa E, et al. Routine offer of antenatal HIV testing ("opt-out" approach) to prevent mother-to-child transmission of HIV in urban Zimbabwe. Bull World Health Organ 2007;85: 843-50.
21. Creek TL, Ntumy R, Seipone K, et al. Successful introduction of routine opt-out HIV testing in antenatal care in Botswana. J Acquir Immune Defic Syndr 2007;45:102-7.
22. Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008;22:1247-56.
23. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007;18:352-58.
24. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health 2008;122: 990-1003.
25. Zhang C, Yang R, Xia X, et al. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. J Acquir Immune Defic Syndr 2002;29:191-96.
26. Garten RJ, Zhang J, Lai S, Liu W, Chen J, Yu XF. Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis 2005; 41(Suppl. 1):S18-24.
27. Ruan Y, Qin G, Yin L, et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS 2007;21(Suppl. 8):S39-46.
28. Wang YC, Xu SH, Li XH, Song AJ, Jia XR, Zhuang H. A study on the prevalence rates of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infections in intravenous drug users. Zhonghua Liu Xing Bing Xue Za Zhi 2006;27:777-79.
29. Garten RJ, Lai SH, Zhang JB, Liu W, Chen J, Yu XF. Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern China. World J Gastroenterol 2008;14:1878-84.
30. Li JR, Gong RY, Tian KL, Wang J, Wang YX, Huang HJ. Study on the blood-borne virus co-infection and T lymphocyte subset among intravenous drug users. World J Gastroenterol 2007;13:2357-62.
31. Liu P, Xiang K, Tang H, et al. Molecular epidemiology of human immunodeficiency virus type 1 and hepatitis C virus in former blood donors in central China. AIDS Res Hum Retroviruses 2008;24:1-6.
32. Qian HZ, Vermund SH, Kaslow RA, et al. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS 2006;20: 1429-35.
33. Qian HZ, Yang Z, Shi X, et al. Hepatitis C virus infection in former commercial plasma/blood donors in rural Shanxi Province, China: the China Integrated Programs for Research on AIDS. J Infect Dis 2005;192: 1694-700.
34. He Y, Zhao QX, Ren YJ, Ding LM. Coinfection with HBV and HCV in 128 AIDS patients infected through blood transmission. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2006; 28:662-64.
35. Xu JQ, Wang JJ, Han LF, et al. Epidemiology, clinical and laboratory characteristics of currently alive HIV-1 infected former blood donors naive to antiretroviral therapy in Anhui Province, China. Chin Med J (Engl) 2006;119: 1941-48.
36. Wang H, Chen RY, Ding G, et al. Prevalence and predictors of HIV infection among female sex workers in Kaiyuan City, Yunnan Province, China. Int J Infect Dis 2009;13: 162-69.